- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04676854
Restoration of Central Vision With the PRIMA System in Patients With Atrophic AMD (PRIMAvera)
February 7, 2023 updated by: Pixium Vision SA
Restoration of Central Vision With the PRIMA System in Patients With Atrophic Age-Related Macular Degeneration
The objective of this study is to evaluate the efficacy and safety of the PRIMA System in patients with atrophic AMD.
Eligible subjects will be implanted with the PRIMA Implant.
The subjects will be assessed with various visual function and functional vision tests at defined timepoints throughout the clinical investigation with the PRIMA System (Implant and Visual Processor).
Study Overview
Status
Active, not recruiting
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Anticipated)
38
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Contact
- Name: Ralf Hornig, PhD
- Phone Number: +33176214742
- Email: clinical-trial@pixium-vision.com
Study Locations
-
-
-
Bordeaux, France, 33000
- Hôpital Pellegrin
-
Créteil, France, 94000
- Centre hospitalier intercommunal de Créteil - Service Ophtalmologie
-
Lyon, France, 69004
- Hôpital de la Croix-Rousse CHU de LYON
-
Marseille, France, 13008
- Centre monticelli Paradis
-
Nantes, France, 44093
- CHU de Nantes
-
Paris, France, 75019
- Fondation Ophtalmologique A. de Rothschild
-
Paris, France, 75012
- Hopital des Quinze Vingts
-
-
-
-
-
Aachen, Germany, 52074
- Universitätsklinikum Aachen, Klinik fuer Augenheilkunde
-
Bonn, Germany, 53127
- Universitats-Augenklinik Bonn
-
Hamburg, Germany, 20251
- Universitätsklinikum Hamburg-Eppendorf (UKE), Augenklinik
-
Ludwigshafen am Rhein, Germany, 67063
- Klinikum Ludwigshafen -Augenklinik
-
Lübeck, Germany, 23538
- Universitätsklinikum Schleswig-Holstein Klinik für Augenheilkunde
-
Munich, Germany, 80336
- Augenklinik der Ludwig-Maximilian Universität München
-
Münster, Germany, 48149
- Universitäts-Augenklinik Münster
-
Sulzbach/Saar, Germany, 66280
- KNAPPSCHAFTSKLINIKUM SAAR GMBH Augenklinik Sulzbach
-
Tübingen, Germany, 72076
- Universitätsklinikum Tübingen
-
Ulm, Germany, 89075
- Universitätsklinikum Ulm
-
-
-
-
-
Roma, Italy, 00133
- Università di Roma Tor Vergata - Policlinico Tor Vergata (PTV), Dipartimento di Medicina Sperimentale - Oftalmologia
-
-
-
-
Schiedamse Vest 160
-
Rotterdam, Schiedamse Vest 160, Netherlands, 3011 BH
- Rotterdam Eye Hospital
-
-
-
-
-
Barcelona, Spain, 08035
- Instituto de Microcirugía Ocular de Barcelona
-
-
-
-
-
London, United Kingdom, 0207 566 2117
- Moorfields Eye Hospital NHS Foundation Trust
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
60 years and older (ADULT, OLDER_ADULT)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Is 60 years or older at the date of inclusion;
- Has a confirmed diagnosis of geographic atrophy due to AMD in both eyes;
- The study eye has best corrected visual acuity of logMAR 1.2 (20/320) or worse as measured by ETDRS test;
- Has an atrophic patch in the study eye including the fovea of at least the implant size (>4.5 mm2 and >2.4 mm in minimum diameter);
- Understands the constraints of the study and accepts to present for all scheduled follow-up visits;
- Patient signed informed consent
Exclusion Criteria:
- Has cataract in the study eye (with LOCS III scale NO, NC, C or P>1); (these patients will be asked to have cataract surgery performed prior to enrollment; all other patients will get IOL replacement during the PRIMA implantation);
- Underwent intra ocular lens implantation in the study eye within the last month ;
- Has a highly myopic study eye (>26 mm AP);
- Has a highly hyperopic study eye (<20 mm AP);
- Has no light perception in either eye;
- Has a history of documented choroidal neovascularization in either eye;
- Has any signs of exudative AMD including exudative AMD with detachment of retinal pigment epithelium in the central visual field of the study eye;
- Has an implanted telescope in one eye;
- Has a black IOL in the study eye;
- Has any disease (other than study allowed diseases) or condition that affects retinal function of the study eye or the visual system (e.g., central retinal artery/vein occlusion, end-stage diabetic retinopathy, Proliferative Diabetic Retinopathy (PDR), diabetic macular edema (DME), severe Non-Proliferative Diabetic Retinopathy (NPDR), retinal detachment, infectious or inflammatory retinal disease, severe glaucoma, optic neuropathy, etc.) ;
- Has any disease or condition that prevents adequate examination (including OCT) of the study eye including, but not limited to media opacities that cannot be resolved prior to implantation. Note, that this criterion is also important for the function of the implant;
- Has a corneal endothelial cell count of less than 1000 cells/mm² in the study eye;
- Suffers from nystagmus or other ocular motility disorders;
- Has any disease or condition that precludes the understanding or communication of the informed consent, study requirements or test protocols (e.g., deafness, severe multiple sclerosis, amyotrophic lateral sclerosis, severe neuritis, etc.);
- Has epileptic seizures;
- Has a known sensitivity to the contact materials of the implant (iridium oxide, silicon-carbide and titanium);
- Has a known allergy to anesthetic drugs;
- Presents with hypotonia in the study eye (<8 mmHg);
- Presents with hypertonia in the study eye (>23 mmHg with treatment);
- Has active cancer or a history of intraocular, optic nerve or brain cancer and metastasis;
- Is an immune-suppressed subject (e.g., due to HIV positive diagnosis, etc.);
- Is a known carrier of multi-resistant microorganisms;
- Is receiving anticoagulation therapy that cannot be adapted to allow eye surgery;
- Is participating in another investigational drug or device study that may interfere with the PRIMAvera study;
- Has a history of chronic or recurrent infection or inflammation that would preclude participation in the study;
Has significant recurrent or chronic inflammations or infections. Specifically, patients with the following disorders are excluded:
- Severe chronic and consuming diseases that frequently associated with infection (e.g. Crohn disease, Whipple's disease);
- Active inflammation in the area of the eye (e.g. herpes of cornea and/or conjunctiva, recurrent blepharoconjunctivitis, hordeolum, chalazion);
- Has a severe psychological disorder;
- Does not have the mental capacity to legally sign the informed consent;
- Has severe renal, cardiac, hepatic, etc. organ diseases (ASA IV or worse);
- Has head dimensions that are incompatible with the PRIMA Glasses;
- Has a refraction of study eye higher than + 4 dpt or lower than - 4 dpt for patients with IOL (there is no refraction criteria for phakic patients, since they get an IOL during PRIMA implantation);
- Has too high and/or unrealistic expectations (e.g., believes that a benefit is guaranteed or expects normal vision after surgery).
The following additional exclusion criteria are applicable for French subjects:
- Is a protected person per French law (e.g. is under guardianship, person deprived of their liberty);
- Is not affiliated to a mandatory social security program (health insurance).
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: NA
- Interventional Model: SINGLE_GROUP
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: PRIMA Bionic Vision System
|
Implantation of PRIMA, Vision training, follow up
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with meaningful improvement of visual acuity
Time Frame: 12 months
|
Proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more from baseline to 12 months
|
12 months
|
Serious Adverse Events
Time Frame: 12 months
|
Number and severity of device and procedure related serious adverse events at 12 months follow-up
|
12 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Proportion of subjects with meaningful improvement of visual acuity
Time Frame: 6, 24, 36 months
|
Proportion of subjects with an improvement of visual acuity of logMAR 0.2 or more at 6, 24 and 36 months compared to baseline
|
6, 24, 36 months
|
Improvement of visual acuity
Time Frame: 6, 12, 24, 36 months
|
Mean improvement of visual acuity at 6, 12, 24 and 36 months compared to baseline
|
6, 12, 24, 36 months
|
Quality of life measured by IVI
Time Frame: 6, 12, 24, 36 months
|
IVI-Impact of Vision Impairment questionnaire (quality of life based on patient reported outcome of functional vision, participation in vision-related daily living activities and emotional well-being) at 6, 12, 24 and 36 months
|
6, 12, 24, 36 months
|
Central visual perception
Time Frame: 12 months
|
Central visual perception with PRIMA at 12 months compared to central visual perception at baseline
|
12 months
|
Adverse Events
Time Frame: 6, 12, 24, 36 months
|
Number and severity of procedure and device related adverse events at 6, 12, 24 and 36 months follow-up
|
6, 12, 24, 36 months
|
Change of natural visual acuity
Time Frame: 6, 12, 24, 36 months
|
Change of natural visual acuity without the PRIMA Glasses
|
6, 12, 24, 36 months
|
Proportion of compliant implantations
Time Frame: 4 weeks after implantation
|
Number of subjects with PRIMA implant placed according protocol
|
4 weeks after implantation
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (ACTUAL)
November 24, 2020
Primary Completion (ANTICIPATED)
February 1, 2024
Study Completion (ANTICIPATED)
February 1, 2026
Study Registration Dates
First Submitted
December 16, 2020
First Submitted That Met QC Criteria
December 16, 2020
First Posted (ACTUAL)
December 21, 2020
Study Record Updates
Last Update Posted (ESTIMATE)
February 9, 2023
Last Update Submitted That Met QC Criteria
February 7, 2023
Last Verified
February 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIP-PV-M
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Geographic Atrophy
-
Aviceda Therapeutics, Inc.RecruitingMacular Degeneration | Geographic Atrophy of the MaculaUnited States
-
GlaxoSmithKlineCompletedAtrophy, GeographicUnited States, Canada
-
GlaxoSmithKlineQuintiles, Inc.Completed
-
Carl Zeiss Meditec, Inc.DataMed Devices Inc.CompletedAdvanced Dry AMD With Geographic AtrophyUnited States
-
Alkeus Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy | Age Related Macular Degeneration | AMD | Atrophy, GeographicUnited States
-
Apellis Pharmaceuticals, Inc.Active, not recruitingGeographic Atrophy Secondary to Age-related Macular DegenerationUnited States, Netherlands, France, Israel, Germany, United Kingdom, Canada, Czechia, Australia, Spain, Italy, Argentina, Brazil, New Zealand, Poland
-
IVERIC bio, Inc.Active, not recruitingMacular Degeneration | Geographic AtrophyUnited States, Latvia, France, Germany, Spain, Hungary, Canada, Israel, Argentina, Czechia, Colombia, Croatia, Italy
-
Boehringer IngelheimCompletedGeographic AtrophyUnited States
-
Genentech, Inc.Completed
-
Apellis Pharmaceuticals, Inc.CompletedGeographic AtrophyUnited States, Australia, New Zealand
Clinical Trials on PRIMA Bionic Vision System
-
Advanced BionicsUnknown
-
Retina Implant AGCompletedRetinal Degeneration | Retinitis PigmentosaGermany, Hungary, United Kingdom
-
Advanced BionicsCompleted
-
University of California, San FranciscoWithdrawnDeafnessUnited States
-
Johnson & Johnson Surgical Vision, Inc.CompletedCataractUnited States, El Salvador
-
Alcon ResearchCompleted
-
Massachusetts General HospitalBoston UniversityCompletedType 1 DiabetesUnited States
-
Poznan University of Medical SciencesCompleted
-
NYU Langone Health7D Surgical Inc.WithdrawnScoliosis | Spinal Stenosis | Spondylolisthesis
-
Alcon ResearchCompleted